First Time Loading...

GT Biopharma Inc
NASDAQ:GTBP

Watchlist Manager
GT Biopharma Inc Logo
GT Biopharma Inc
NASDAQ:GTBP
Watchlist
Price: 3.7516 USD 2.78% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

GTBP's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager pl... [ Read More ]

The intrinsic value of one GTBP stock under the Base Case scenario is 10.12 USD. Compared to the current market price of 3.7516 USD, GT Biopharma Inc is Undervalued by 63%.

Key Points:
GTBP Intrinsic Value
Base Case
10.12 USD
Undervaluation 63%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
GT Biopharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GTBP stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
GT Biopharma Inc

Provide an overview of the primary business activities
of GT Biopharma Inc.

What unique competitive advantages
does GT Biopharma Inc hold over its rivals?

What risks and challenges
does GT Biopharma Inc face in the near future?

Has there been any significant insider trading activity
in GT Biopharma Inc recently?

Summarize the latest earnings call
of GT Biopharma Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for GT Biopharma Inc.

Provide P/S
for GT Biopharma Inc.

Provide P/E
for GT Biopharma Inc.

Provide P/OCF
for GT Biopharma Inc.

Provide P/FCFE
for GT Biopharma Inc.

Provide P/B
for GT Biopharma Inc.

Provide EV/S
for GT Biopharma Inc.

Provide EV/GP
for GT Biopharma Inc.

Provide EV/EBITDA
for GT Biopharma Inc.

Provide EV/EBIT
for GT Biopharma Inc.

Provide EV/OCF
for GT Biopharma Inc.

Provide EV/FCFF
for GT Biopharma Inc.

Provide EV/IC
for GT Biopharma Inc.

Show me price targets
for GT Biopharma Inc made by professional analysts.

What are the Revenue projections
for GT Biopharma Inc?

How accurate were the past Revenue estimates
for GT Biopharma Inc?

What are the Net Income projections
for GT Biopharma Inc?

How accurate were the past Net Income estimates
for GT Biopharma Inc?

What are the EPS projections
for GT Biopharma Inc?

How accurate were the past EPS estimates
for GT Biopharma Inc?

What are the EBIT projections
for GT Biopharma Inc?

How accurate were the past EBIT estimates
for GT Biopharma Inc?

Compare the revenue forecasts
for GT Biopharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of GT Biopharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of GT Biopharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of GT Biopharma Inc compared to its peers.

Compare the P/E ratios
of GT Biopharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing GT Biopharma Inc with its peers.

Analyze the financial leverage
of GT Biopharma Inc compared to its main competitors.

Show all profitability ratios
for GT Biopharma Inc.

Provide ROE
for GT Biopharma Inc.

Provide ROA
for GT Biopharma Inc.

Provide ROIC
for GT Biopharma Inc.

Provide ROCE
for GT Biopharma Inc.

Provide Gross Margin
for GT Biopharma Inc.

Provide Operating Margin
for GT Biopharma Inc.

Provide Net Margin
for GT Biopharma Inc.

Provide FCF Margin
for GT Biopharma Inc.

Show all solvency ratios
for GT Biopharma Inc.

Provide D/E Ratio
for GT Biopharma Inc.

Provide D/A Ratio
for GT Biopharma Inc.

Provide Interest Coverage Ratio
for GT Biopharma Inc.

Provide Altman Z-Score Ratio
for GT Biopharma Inc.

Provide Quick Ratio
for GT Biopharma Inc.

Provide Current Ratio
for GT Biopharma Inc.

Provide Cash Ratio
for GT Biopharma Inc.

What is the historical Revenue growth
over the last 5 years for GT Biopharma Inc?

What is the historical Net Income growth
over the last 5 years for GT Biopharma Inc?

What is the current Free Cash Flow
of GT Biopharma Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for GT Biopharma Inc.

Financials

Balance Sheet Decomposition
GT Biopharma Inc

Current Assets 14.1m
Cash & Short-Term Investments 14m
Other Current Assets 84k
Non-Current Assets 53k
PP&E 53k
Current Liabilities 6.6m
Accounts Payable 4.3m
Accrued Liabilities 1.3m
Other Current Liabilities 1.1m
Efficiency

Earnings Waterfall
GT Biopharma Inc

Revenue
0 USD
Operating Expenses
-13.6m USD
Operating Income
-13.6m USD
Other Expenses
6m USD
Net Income
-7.6m USD

Free Cash Flow Analysis
GT Biopharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

GTBP Profitability Score
Profitability Due Diligence

GT Biopharma Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional ROIC
ROE is Increasing
Negative Free Cash Flow
47/100
Profitability
Score

GT Biopharma Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

GTBP Solvency Score
Solvency Due Diligence

GT Biopharma Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
41/100
Solvency
Score

GT Biopharma Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GTBP Price Targets Summary
GT Biopharma Inc

There are no price targets for GTBP.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

GTBP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

GTBP Price
GT Biopharma Inc

1M 1M
-15%
6M 6M
-51%
1Y 1Y
-66%
3Y 3Y
-99%
5Y 5Y
-98%
10Y 10Y
-100%
Annual Price Range
3.7516
52w Low
3.65
52w High
11.406
Price Metrics
Average Annual Return 34.72%
Standard Deviation of Annual Returns 201.41%
Max Drawdown -99%
Shares Statistics
Market Capitalization 5.2m USD
Shares Outstanding 1 380 630
Percentage of Shares Shorted 0.66%

GTBP Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

GT Biopharma Inc Logo
GT Biopharma Inc

Country

United States of America

Industry

Biotechnology

Market Cap

5.2m USD

Dividend Yield

0%

Description

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in Brisbane California, California and currently employs 8 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The firm's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The firm is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).

Contact

CALIFORNIA
Brisbane California
8000 Marina Blvd, Suite 100
+18003049888.0
https://www.gtbiopharma.com/

IPO

2013-10-22

Employees

8

Officers

Interim CEO & Executive Chairman
Mr. Michael Martin Breen
CFO & Secretary
Mr. Manu Ohri
Consulting Chief Scientific Officer, Consulting Chief Medical Officer & Scientific Advisor
Dr. Jeffrey S. Miller M.D.

See Also

Discover More
What is the Intrinsic Value of one GTBP stock?

The intrinsic value of one GTBP stock under the Base Case scenario is 10.12 USD.

Is GTBP stock undervalued or overvalued?

Compared to the current market price of 3.7516 USD, GT Biopharma Inc is Undervalued by 63%.